甫康药业冲刺港股IPO:6年估值增长33倍,九州通、药明生物参股

瑞财经
Sep 01, 2025

瑞财经 刘治颖8月31日,甫康生物科技(上海)股份有限公司(以下简称:甫康药业)向港交所主板递交上市申请,农银国际、民银资本、复星国际资本为联席保荐人。甫康药业成立于2015年11月,是一家商业化阶段生物医药公司。其专注于开发癌症相关疾病治疗领域的突破性疗法,同时兼顾针对病毒和衰老疾病领域创新药物的开发及商业化。公司采取商业化与临床开发并重的双轨策略,而非单纯聚焦研发。甫康药业的核心产品包括:...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10